HealthyStimCerveletNCT07561229
Effects of Repetitive Transcranial Magnetic Stimulation on Two Cerebellar Targets
A study testing Active rTMS - Lobule VIII, Active rTMS - Crus I/II and Cognitive and Motor Assessment Battery in people with Healthy and Healthy Adult, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
The purpose of this study is to understand how different areas of the cerebellum (a part of the brain) control different functions and how they can be influenced by non-invasive brain stimulation. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy, Healthy Adult
- What is being tested?
- Active rTMS - Lobule VIII, Active rTMS - Crus I/II and Cognitive and Motor Assessment Battery
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteFrance
- Study dates
- 1 Sep 2026to 2 Jan 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Subject, male or female, aged between 18 and 60 years inclusive
- Subject affiliated with or a beneficiary of a social security health insurance scheme
- Subject has dated and signed the informed consent form prior to the start of any trial-related procedures
- For women of childbearing potential, a negative urinary pregnancy test and the use of effective contraception throughout the duration of the study
Who cannot join
- Subject with substance use disorders (as defined by the DSM-5)
- Subject having taken benzodiazepines and related compounds (within the period preceding inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (within the 2 months preceding inclusion), or hallucinogenic substances (within the period preceding inclusion, for a duration equivalent to 5 half-lives of the product)
- Subject suffering from a neurological pathology or sequelae
- Subject with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Subject with Borderline Personality Disorder
- Subject presenting with disabling sensory impairments, specifically a visual acuity (corrected, if applicable) < 0.8 (due to the use of visual materials; Freiburg Vision Test, Bach 1996; verified during an examination at the screening visit)
Show all 12Show fewer
- Subject deprived of liberty or under legal protection
- Subject under guardianship or trusteeship
- Pregnant or breastfeeding woman (verified by a urinary test at the screening visit)
- Subject within an exclusion period defined by another clinical study or participating in a study likely to impact the results of the research
- Subject presenting a contraindication for fMRI or rTMS: presence of non-removable ferromagnetic bodies, prostheses, pacemakers, implanted medication pumps, vascular clips or stents, heart valves or ventricular shunts, certain intracerebral clips, cochlear implants, history of seizures (epilepsy), or skin breach/pathology at the point of contact with the electrodes
- Subject with a history of major neurological or psychiatric disease with current psychotropic medication (i.e., antipsychotics, benzodiazepines and related compounds, or hypnotics)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091
Anne GIERSCH, +33(0)3 88 11 64 71 ext. +33, giersch@unistra.fr
About this study
Official title: Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Two Cerebellar Targets (Lobule VIII vs. CRUS I/II)
The purpose of this study is to understand how different areas of the cerebellum (a part of the brain) control different functions and how they can be influenced by non-invasive brain stimulation.
While researchers know that repetitive Transcranial Magnetic Stimulation (rTMS) can have positive effects on conditions like stroke and schizophrenia, they do not yet fully understand which specific stimulation settings work best or which exact parts of the cerebellum should be targeted for different symptoms.
Read more
This study compares the effects of stimulation on two specific regions:
- Lobule VIII: Linked to movement and motor learning.
- CRUS I/II: Linked to attention, thinking (cognition), and predicting the timing of events.By comparing these areas, researchers hope to gain the information needed to develop better treatments for neurological and psychiatric disorders.
This is a randomized, double-blind study involving 40 healthy volunteers. Participants will be split into two groups:
- Group 1: Receives "exciting" (activity-increasing) stimulation.
- Group 2: Receives "inhibiting" (activity-decreasing) stimulation.
Each participant will attend three different test sessions in a random order:
- rTMS targeting Lobule VIII
- rTMS targeting CRUS I/II
- Placebo (Sham) stimulation that looks and feels like the real thing but does not affect the brain.
During each session, researchers will use brain imaging (fMRI) and computerized tasks to measure changes in brain connectivity and performance in motor and cognitive activities.
There is no direct medical benefit to the participants. However, the results will help scientists create better therapies for patients with brain-related health issues The risks are considered minimal. Common side effects of rTMS include temporary mild headaches or a clicking sound during stimulation. MRI scans can sometimes cause mild discomfort or a feeling of closed-in spaces (claustrophobia). Researchers have put safety measures in place, such as hearing protection and constant medical supervision during scans, to minimize these risks.
- Conditions
- Healthy, Healthy Adult
- Being tested
- Active rTMS - Lobule VIII, Active rTMS - Crus I/II, Sham rTMS, Cognitive and Motor Assessment Battery
- Keywords
- Repetitive Transcranial Magnetic Stimulation (rTMS), Cerebellum, Lobule VIII, Crus I/II, Resting-state functional Magnetic Resonance Imaging (rs-fMRI), Neuromodulation, Neuroplasticity, Excitatory vs. Inhibitory Stimulation, Neurotypical
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active rTMS - Lobule VIIIDevice
Either excitatory (e.g., iTBS) or inhibitory (e.g., cTBS) depending on the assigned group.
Active rTMS - Crus I/IIDevice
Participants receive rTMS targeting the Crus I/II of the cerebellum. Either excitatory (e.g., iTBS) or inhibitory (e.g., cTBS) depending on the assigned group.
Sham rTMSDevice
Also called Placebo, Sham
The coil looks and sounds identical to the active coil and is placed in the same positions (counterbalanced between Lobule VIII and Crus I/II sites). It provides the physical sensation and auditory "click" of TMS without delivering a significant magnetic field to the brain tissue, maintaining the study's double-blind integrity.
Cognitive and Motor Assessment BatteryBehavioural
Participants perform three computerized tasks to evaluate the functional impact of the rTMS:
- Visuomotor Task: A joystick-based task assessing motor coordination and learning (linked to Lobule VIII).
- Temporal Prediction Task: A visual task requiring the participant to predict the timing of an event (linked to Crus I/II).
- Mental Imagery \& Finger Tapping: A task assessing the cognitive representation of movement.
| Study group | Role | What they receive |
|---|---|---|
| 1 - Lobule VIII - Crus I/II - Sham Sequence - Excitatory | Experimental | Participants receive active rTMS to Lobule VIII in the first session, followed by active rTMS to Crus I/II in the second, and Sham stimulation in the third. Receives: Device: Active rTMS - Lobule VIII; Device: Active rTMS - Crus I/II; Device: Sham rTMS; Behavioral: Cognitive and Motor Assessment Battery |
| 2 - Lobule VIII - Sham - Crus I/II Sequence - Excitatory | Experimental | Participants receive active rTMS to Lobule VIII, followed by Sham stimulation, and finally active rTMS to Crus I/II. Receives: Device: Active rTMS - Lobule VIII; Device: Active rTMS - Crus I/II; Device: Sham rTMS; Behavioral: Cognitive and Motor Assessment Battery |
| 3 - Crus I/II - Lobule VIII - Sham Sequence - Excitatory | Experimental | Participants receive active rTMS to Crus I/II, followed by active rTMS to Lobule VIII, and finally Sham stimulation. Receives: Device: Active rTMS - Lobule VIII; Device: Active rTMS - Crus I/II; Device: Sham rTMS; Behavioral: Cognitive and Motor Assessment Battery |
| 4 - Crus I/II - Sham - Lobule VIII Sequence - Excitatory | Experimental | Participants receive active rTMS to Crus I/II, followed by Sham stimulation, and finally active rTMS to Lobule VIII. Receives: Device: Active rTMS - Lobule VIII; Device: Active rTMS - Crus I/II; Device: Sham rTMS; Behavioral: Cognitive and Motor Assessment Battery |
| 5 - Sham - Lobule VIII - Crus I/II Sequence - Excitatory | Experimental | Participants receive Sham stimulation first, followed by active rTMS to Lobule VIII and active rTMS to Crus I/II. Receives: Device: Active rTMS - Lobule VIII; Device: Active rTMS - Crus I/II; Device: Sham rTMS; Behavioral: Cognitive and Motor Assessment Battery |
| 6 - Sham - Crus I/II - Lobule VIII Sequence - Excitatory | Experimental | Participants receive Sham stimulation first, followed by active rTMS to Crus I/II and active rTMS to Lobule VIII Receives: Device: Active rTMS - Lobule VIII; Device: Active rTMS - Crus I/II; Device: Sham rTMS; Behavioral: Cognitive and Motor Assessment Battery |
| 1 - Lobule VIII - Crus I/II - Sham Sequence - inhibitory | Experimental | Not described Receives: Device: Active rTMS - Lobule VIII; Device: Active rTMS - Crus I/II; Device: Sham rTMS; Behavioral: Cognitive and Motor Assessment Battery |
| 2 - Lobule VIII - Sham - Crus I/II Sequence - inhibitory | Experimental | Not described Receives: Device: Active rTMS - Lobule VIII; Device: Active rTMS - Crus I/II; Device: Sham rTMS; Behavioral: Cognitive and Motor Assessment Battery |
| 3 - Crus I/II - Lobule VIII - Sham Sequence - inhibitory | Experimental | Not described Receives: Device: Active rTMS - Lobule VIII; Device: Active rTMS - Crus I/II; Device: Sham rTMS; Behavioral: Cognitive and Motor Assessment Battery |
| 4 - Crus I/II - Sham - Lobule VIII Sequence - Inhibitory | Experimental | Not described Receives: Device: Active rTMS - Lobule VIII; Device: Active rTMS - Crus I/II; Device: Sham rTMS; Behavioral: Cognitive and Motor Assessment Battery |
| 5 - Sham - Lobule VIII - Crus I/II Sequence - Inhibitory | Experimental | Not described Receives: Device: Active rTMS - Lobule VIII; Device: Active rTMS - Crus I/II; Device: Sham rTMS; Behavioral: Cognitive and Motor Assessment Battery |
| 6 - Sham - Crus I/II - Lobule VIII Sequence - Inhibitory | Experimental | Not described Receives: Device: Active rTMS - Lobule VIII; Device: Active rTMS - Crus I/II; Device: Sham rTMS; Behavioral: Cognitive and Motor Assessment Battery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Resting-State Functional Connectivity (RSFC) Measured by functional Magnetic Resonance Imaging (fMRI, expressed as Fisher's z-transformed correlation coefficients) within Cerebellar-Thalamo-Frontal and Cerebellar-Parieto-Motor Networks.
Functional imaging data will be pre-processed according to standard procedures: slice-timing correction, intra-run spatial realignement, inter-run realignement, distortion and motion artifact correction, band-pass filtering to remove physiological noise, and normalization into the MNI common space, followed by smoothing using FSL and SPM12 software.Subsequently, the signal within the networks of interest will be extracted using the "Conn" toolbox and compared using a General Linear Model (GLM). Connectivity maps will be generated from specific "seed" regions of interest (Crus I/II and lobule VIII), where each voxel value corresponds to the correlation with the seed region.
Measured: Baseline (Pre-stimulation) and 1-hour post-stimulation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2026
- Study start1 Sep 2026 (estimated)
- Primary completion2 Jan 2030 (estimated)
- Study completion2 Jan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Collaborators
- ICube Laboratory
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07561229
- Sponsor's protocol ID
- RC26_0179
- Acronym
- StimCervelet
- Status last verified
- Apr 2026
- First submitted
- 17 Apr 2026
- Last updated
- 1 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Two Cerebellar Targets (Lobule VIII vs. CRUS I/II)
- ClinicalTrials.gov ID
- NCT07561229
- Acronym / sponsor ID
- StimCervelet / RC26_0179
- Conditions
- Healthy, Healthy Adult
- Keywords
- Repetitive Transcranial Magnetic Stimulation (rTMS), Cerebellum, Lobule VIII, Crus I/II, Resting-state functional Magnetic Resonance Imaging (rs-fMRI), Neuromodulation, Neuroplasticity, Excitatory vs. Inhibitory Stimulation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Collaborators
- ICube Laboratory
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 2 Jan 2030 (estimated)
- Study completion
- 2 Jan 2030 (estimated)
- First posted
- 1 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to understand how different areas of the cerebellum (a part of the brain) control different functions and how they can be influenced by non-invasive brain stimulation.
While researchers know that repetitive Transcranial Magnetic Stimulation (rTMS) can have positive effects on conditions like stroke and schizophrenia, they do not yet fully understand which specific stimulation settings work best or which exact parts of the cerebellum should be targeted for different symptoms.
This study compares the effects of stimulation on two specific regions:
- Lobule VIII: Linked to movement and motor learning.
- CRUS I/II: Linked to attention, thinking (cognition), and predicting the timing of events.By comparing these areas, researchers hope to gain the information needed to develop better treatments for neurological and psychiatric disorders.
This is a randomized, double-blind study involving 40 healthy volunteers. Participants will be split into two groups:
- Group 1: Receives "exciting" (activity-increasing) stimulation.
- Group 2: Receives "inhibiting" (activity-decreasing) stimulation.
Each participant will attend three different test sessions in a random order:
- rTMS targeting Lobule VIII
- rTMS targeting CRUS I/II
- Placebo (Sham) stimulation that looks and feels like the real thing but does not affect the brain.
During each session, researchers will use brain imaging (fMRI) and computerized tasks to measure changes in brain connectivity and performance in motor and cognitive activities.
There is no direct medical benefit to the participants. However, the results will help scientists create better therapies for patients with brain-related health issues The risks are considered minimal. Common side effects of rTMS include temporary mild headaches or a clicking sound during stimulation. MRI scans can sometimes cause mild discomfort or a feeling of closed-in spaces (claustrophobia). Researchers have put safety measures in place, such as hearing protection and constant medical supervision during scans, to minimize these risks.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 12
| Arm | Type | Receives |
|---|---|---|
| 1 - Lobule VIII - Crus I/II - Sham Sequence - Excitatory | Experimental | Device: Active rTMS - Lobule VIII, Device: Active rTMS - Crus I/II, Device: Sham rTMS, Behavioral: Cognitive and Motor Assessment BatteryParticipants receive active rTMS to Lobule VIII in the first session, followed by active rTMS to Crus I/II in the second, and Sham stimulation in the third. |
| 2 - Lobule VIII - Sham - Crus I/II Sequence - Excitatory | Experimental | Device: Active rTMS - Lobule VIII, Device: Active rTMS - Crus I/II, Device: Sham rTMS, Behavioral: Cognitive and Motor Assessment BatteryParticipants receive active rTMS to Lobule VIII, followed by Sham stimulation, and finally active rTMS to Crus I/II. |
| 3 - Crus I/II - Lobule VIII - Sham Sequence - Excitatory | Experimental | Device: Active rTMS - Lobule VIII, Device: Active rTMS - Crus I/II, Device: Sham rTMS, Behavioral: Cognitive and Motor Assessment BatteryParticipants receive active rTMS to Crus I/II, followed by active rTMS to Lobule VIII, and finally Sham stimulation. |
| 4 - Crus I/II - Sham - Lobule VIII Sequence - Excitatory | Experimental | Device: Active rTMS - Lobule VIII, Device: Active rTMS - Crus I/II, Device: Sham rTMS, Behavioral: Cognitive and Motor Assessment BatteryParticipants receive active rTMS to Crus I/II, followed by Sham stimulation, and finally active rTMS to Lobule VIII. |
| 5 - Sham - Lobule VIII - Crus I/II Sequence - Excitatory | Experimental | Device: Active rTMS - Lobule VIII, Device: Active rTMS - Crus I/II, Device: Sham rTMS, Behavioral: Cognitive and Motor Assessment BatteryParticipants receive Sham stimulation first, followed by active rTMS to Lobule VIII and active rTMS to Crus I/II. |
| 6 - Sham - Crus I/II - Lobule VIII Sequence - Excitatory | Experimental | Device: Active rTMS - Lobule VIII, Device: Active rTMS - Crus I/II, Device: Sham rTMS, Behavioral: Cognitive and Motor Assessment BatteryParticipants receive Sham stimulation first, followed by active rTMS to Crus I/II and active rTMS to Lobule VIII |
| 1 - Lobule VIII - Crus I/II - Sham Sequence - inhibitory | Experimental | Device: Active rTMS - Lobule VIII, Device: Active rTMS - Crus I/II, Device: Sham rTMS, Behavioral: Cognitive and Motor Assessment Battery |
| 2 - Lobule VIII - Sham - Crus I/II Sequence - inhibitory | Experimental | Device: Active rTMS - Lobule VIII, Device: Active rTMS - Crus I/II, Device: Sham rTMS, Behavioral: Cognitive and Motor Assessment Battery |
| 3 - Crus I/II - Lobule VIII - Sham Sequence - inhibitory | Experimental | Device: Active rTMS - Lobule VIII, Device: Active rTMS - Crus I/II, Device: Sham rTMS, Behavioral: Cognitive and Motor Assessment Battery |
| 4 - Crus I/II - Sham - Lobule VIII Sequence - Inhibitory | Experimental | Device: Active rTMS - Lobule VIII, Device: Active rTMS - Crus I/II, Device: Sham rTMS, Behavioral: Cognitive and Motor Assessment Battery |
| 5 - Sham - Lobule VIII - Crus I/II Sequence - Inhibitory | Experimental | Device: Active rTMS - Lobule VIII, Device: Active rTMS - Crus I/II, Device: Sham rTMS, Behavioral: Cognitive and Motor Assessment Battery |
| 6 - Sham - Crus I/II - Lobule VIII Sequence - Inhibitory | Experimental | Device: Active rTMS - Lobule VIII, Device: Active rTMS - Crus I/II, Device: Sham rTMS, Behavioral: Cognitive and Motor Assessment Battery |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Subject, male or female, aged between 18 and 60 years inclusive
- Subject affiliated with or a beneficiary of a social security health insurance scheme
- Subject has dated and signed the informed consent form prior to the start of any trial-related procedures
- For women of childbearing potential, a negative urinary pregnancy test and the use of effective contraception throughout the duration of the study
Key exclusion criteria (12 listed)
- Subject with substance use disorders (as defined by the DSM-5)
- Subject having taken benzodiazepines and related compounds (within the period preceding inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (within the 2 months preceding inclusion), or hallucinogenic substances (within the period preceding inclusion, for a duration equivalent to 5 half-lives of the product)
- Subject suffering from a neurological pathology or sequelae
- Subject with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Subject with Borderline Personality Disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active rTMS - Lobule VIIIEither excitatory (e.g., iTBS) or inhibitory (e.g., cTBS) depending on the assigned group. | Device | 1 - Lobule VIII - Crus I/II - Sham Sequence - Excitatory, 1 - Lobule VIII - Crus I/II - Sham Sequence - inhibitory, 2 - Lobule VIII - Sham - Crus I/II Sequence - Excitatory, 2 - Lobule VIII - Sham - Crus I/II Sequence - inhibitory, 3 - Crus I/II - Lobule VIII - Sham Sequence - Excitatory, 3 - Crus I/II - Lobule VIII - Sham Sequence - inhibitory, 4 - Crus I/II - Sham - Lobule VIII Sequence - Excitatory, 4 - Crus I/II - Sham - Lobule VIII Sequence - Inhibitory, 5 - Sham - Lobule VIII - Crus I/II Sequence - Excitatory, 5 - Sham - Lobule VIII - Crus I/II Sequence - Inhibitory, 6 - Sham - Crus I/II - Lobule VIII Sequence - Excitatory, 6 - Sham - Crus I/II - Lobule VIII Sequence - Inhibitory |
| Active rTMS - Crus I/IIParticipants receive rTMS targeting the Crus I/II of the cerebellum. Either excitatory (e.g., iTBS) or inhibitory (e.g., cTBS) depending on the assigned group. | Device | 1 - Lobule VIII - Crus I/II - Sham Sequence - Excitatory, 1 - Lobule VIII - Crus I/II - Sham Sequence - inhibitory, 2 - Lobule VIII - Sham - Crus I/II Sequence - Excitatory, 2 - Lobule VIII - Sham - Crus I/II Sequence - inhibitory, 3 - Crus I/II - Lobule VIII - Sham Sequence - Excitatory, 3 - Crus I/II - Lobule VIII - Sham Sequence - inhibitory, 4 - Crus I/II - Sham - Lobule VIII Sequence - Excitatory, 4 - Crus I/II - Sham - Lobule VIII Sequence - Inhibitory, 5 - Sham - Lobule VIII - Crus I/II Sequence - Excitatory, 5 - Sham - Lobule VIII - Crus I/II Sequence - Inhibitory, 6 - Sham - Crus I/II - Lobule VIII Sequence - Excitatory, 6 - Sham - Crus I/II - Lobule VIII Sequence - Inhibitory |
| Sham rTMSAlso: Placebo, ShamThe coil looks and sounds identical to the active coil and is placed in the same positions (counterbalanced between Lobule VIII and Crus I/II sites). It provides the physical sensation and auditory "click" of TMS without delivering a significant magnetic field to the brain tissue, maintaining the study's double-blind integrity. | Device | 1 - Lobule VIII - Crus I/II - Sham Sequence - Excitatory, 1 - Lobule VIII - Crus I/II - Sham Sequence - inhibitory, 2 - Lobule VIII - Sham - Crus I/II Sequence - Excitatory, 2 - Lobule VIII - Sham - Crus I/II Sequence - inhibitory, 3 - Crus I/II - Lobule VIII - Sham Sequence - Excitatory, 3 - Crus I/II - Lobule VIII - Sham Sequence - inhibitory, 4 - Crus I/II - Sham - Lobule VIII Sequence - Excitatory, 4 - Crus I/II - Sham - Lobule VIII Sequence - Inhibitory, 5 - Sham - Lobule VIII - Crus I/II Sequence - Excitatory, 5 - Sham - Lobule VIII - Crus I/II Sequence - Inhibitory, 6 - Sham - Crus I/II - Lobule VIII Sequence - Excitatory, 6 - Sham - Crus I/II - Lobule VIII Sequence - Inhibitory |
| Cognitive and Motor Assessment BatteryParticipants perform three computerized tasks to evaluate the functional impact of the rTMS: * Visuomotor Task: A joystick-based task assessing motor coordination and learning (linked to Lobule VIII). * Temporal Prediction Task: A visual task requiring the participant to predict the timing of an event (linked to Crus I/II). * Mental Imagery \& Finger Tapping: A task assessing the cognitive representation of movement. | Behavioural | 1 - Lobule VIII - Crus I/II - Sham Sequence - Excitatory, 1 - Lobule VIII - Crus I/II - Sham Sequence - inhibitory, 2 - Lobule VIII - Sham - Crus I/II Sequence - Excitatory, 2 - Lobule VIII - Sham - Crus I/II Sequence - inhibitory, 3 - Crus I/II - Lobule VIII - Sham Sequence - Excitatory, 3 - Crus I/II - Lobule VIII - Sham Sequence - inhibitory, 4 - Crus I/II - Sham - Lobule VIII Sequence - Excitatory, 4 - Crus I/II - Sham - Lobule VIII Sequence - Inhibitory, 5 - Sham - Lobule VIII - Crus I/II Sequence - Excitatory, 5 - Sham - Lobule VIII - Crus I/II Sequence - Inhibitory, 6 - Sham - Crus I/II - Lobule VIII Sequence - Excitatory, 6 - Sham - Crus I/II - Lobule VIII Sequence - Inhibitory |
Primary outcome
Change in Resting-State Functional Connectivity (RSFC) Measured by functional Magnetic Resonance Imaging (fMRI, expressed as Fisher's z-transformed correlation coefficients) within Cerebellar-Thalamo-Frontal and Cerebellar-Parieto-Motor Networks.
Time frame: Baseline (Pre-stimulation) and 1-hour post-stimulation
Functional imaging data will be pre-processed according to standard procedures: slice-timing correction, intra-run spatial realignement, inter-run realignement, distortion and motion artifact correction, band-pass filtering to remove physiological noise, and normalization into the MNI common space, followed by smoothing using FSL and SPM12 software.Subsequently, the signal within the networks of interest will be extracted using the "Conn" toolbox and compared using a General Linear Model (GLM). Connectivity maps will be generated from specific "seed" regions of interest (Crus I/II and lobule VIII), where each voxel value corresponds to the correlation with the seed region.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle
Brain Mapping, Healthy Volunteer
Enrolling by invitationObservational study
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
Healthy Volunteer Samples
Recruiting
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
Improving Healthy Food Access in Food Insecurity Populations in Normal and Emergency Situations
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
Recruiting
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
Healthy Volunteer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active rTMS - Lobule VIII, Active rTMS - Crus I/II and Cognitive and Motor Assessment Battery in people with Healthy and Healthy Adult, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Anne GIERSCH (+33(0)3 88 11 64 71 ext. +33, giersch@unistra.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Resting-State Functional Connectivity (RSFC) Measured by functional Magnetic Resonance Imaging (fMRI, expressed as Fisher's z-transformed correlation coefficients) within Cerebellar-Thalamo-Frontal and Cerebellar-Parieto-Motor Networks. (time frame: Baseline (Pre-stimulation) and 1-hour post-stimulation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.